The FDA approved SimpleScreen CRC as a screening option for colorectal cancer in adults 45 years of age and older at average risk for the disease.
News|Articles|March 5, 2026
- Vol.27/No.5
- Volume 27
- Issue 05
Rising Incidence, Unclear Drivers: Knowledge Gaps Persist in Early-Onset CRC
Author(s)Courtney Flaherty
Fact checked by: Kyle Doherty , Kirsty Mackay
John L. Marshall, MD, and Christopher Lieu, MD, comment on the rising incidence of early-onset colorectal cancer (CRC) during CRC Awareness Month.
Advertisement
Advertisement
Colorectal cancer (CRC) incidence among adults younger than 50 years has nearly doubled since the 1990s, transforming what was once a projected trend into a present-day clinical crisis.1 By 2030, CRC is projected to increase in incidence by 90%, and recent data show that the disease is already the leading cause of cancer-related death among men and women younger than 50 years.1,2
Related to this article
Faculty reviewed data-driven advances in treatment intensification, sequencing, and emerging biomarkers across the prostate cancer and RCC continuums.
PRAME-directed therapies represent a novel approach in the treatment of advanced melanoma.
The FDA approved gedatolisib in PIK3CA wild-type breast cancer, granted full approval to selpercatinib in RET fusion+ tumors, and more.
Laure-Anne Teuwen, MD, PhD, debates the real-world advantages of subcutaneous pembrolizumab.
A phase 2 study of neoadjuvant cemiplimab in HHI-naive BCC of the head and neck produced a 60.1% ORR and a 42.9% surgical benefit rate.
Nirav N. Shah, MD, MSHP, and Alexey Danilov, MD, PhD, discuss the phase 2 DAYBreak CLL-201 trial evaluating bexobrutideg in relapsed/refractory CLL.
The CDH17-targeting antibody-drug conjugate received the designation for previously treated advanced unresectable or metastatic colorectal cancer.
Advertisement
Advertisement